Shares of Huntington Bancshares (NASDAQ:HBAN) saw a large growth in short interest during the month…
On Dec 09, Zymeworks Inc. announced the extension of a research collaboration with Merck &…
BP p.l.c. (NYSE:BP) is to ax middle managers and could freeze projects as it grapples…
Polycom (NASDAQ:PLCM) has received an average rating of “Buy” from the nine analysts that are…
Shares of Huntington Bancshares (NASDAQ:HBAN) saw a large growth in short interest during the month of November. As of November 28th, there was short interest totalling 18,600,104 shares, a growth of 9.6% from the November 14th total of 16,968,635 shares, Analyst Ratings Network.com reports. Huntington Bancshares Incorporated (NASDAQ:HBAN) belongs to Financial sector. Its net profit…
On Dec 09, Zymeworks Inc. announced the extension of a research collaboration with Merck & Co. Inc. (NYSE:MRK), known as MSD outside the United States and Canada, that was originally announced in August 2011. In addition, Merck gains expanded access to Zymeworks’ proprietary Azymetric™ platform for the development of novel bi-specific antibody therapeutic candidates. Merck…
BP p.l.c. (NYSE:BP) is to ax middle managers and could freeze projects as it grapples with the plummeting oil price, The Sunday Times reported, citing finance director Brian Gilvary. BP p.l.c. (NYSE:BP) belongs to Basic Materials sector. Its net profit margin is 2.50% and weekly performance is -10.11%. On last trading day company shares ended…
Polycom (NASDAQ:PLCM) has received an average rating of “Buy” from the nine analysts that are presently covering the company, American Banking & Market News reports. Polycom, Inc. (NASDAQ:PLCM) shares increased 0.15% in last trading session and ended the day at $12.95. PLCM Gross Margin is 58.10% and its return on assets is 1.10%. Polycom, Inc….
Semiconductor chipmaker, Marvell Technology Group Ltd. (NASDAQ:MRVL) recently authorized an additional stock repurchase program, thereby maintaining the trend of returning wealth to its shareholders from time to time, depending on market conditions. Under this program, the company is authorized to repurchase up to $250 million of its common stock. Marvell Technology Group Ltd. (NASDAQ:MRVL) belongs…
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), hosted a conference where data was presented using Manocept™ platform compound, tilmanocept, that was generated by independent academic collaborators with expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular disease therapeutic areas. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) belongs to Healthcare sector. Its…
Tech Analysis & Market News